Skip to main content
. Author manuscript; available in PMC: 2012 Dec 8.
Published in final edited form as: Cancer Lett. 2011 Aug 6;311(2):219–229. doi: 10.1016/j.canlet.2011.07.023

Table 3.

Summary of plasma and intra-tumor drug concentrations after treatments

% change1 Irinotecan concentration SN-38 concentration
(combination vs. drug alone) Plasma A253 FaDu Plasma A253 FaDu
Concurrent schedule2 6 −13 −12 −1 44 −31
Sequential schedule (d7)3 92*** 45 16 23 56 61
Sequential schedule (d14)4 32 ND −60*** 23*** ND 124***
1

Compared to irinotecan alone

2

MSC (0.2 mg/mouse) + irinotecan (100mg/kg)

3

MSC (0.2 mg/mouse/d) 7d prior to and then concurrently with irinotecan (100mg/kg×1)

4

MSC (0.2 mg/mouse/d) 7d prior to and then concurrently with irinotecan (100mg/kg×2)

***

p<0.001 when compared with irinotecan alone